Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228280 | PMC |
| http://dx.doi.org/10.1111/ajt.15905 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis.
Eur J Hosp Pharm
January 2025
Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain
Background: Tachyphylaxis is the rapid development of drug tolerance following repeated administration.
Objectives: To evaluate the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) data for drugs significantly associated with tachyphylaxis using disproportionality analysis.
Methods: Disproportionality analysis was used for detecting safety signals for identifying drugs associated with tachyphylaxis.
A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.
Immun Inflamm Dis
December 2024
Department of Rheumatology and Immunology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Objective: This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement.
Methods: Totally 355 newly diagnosed BD patients with mucocutaneous involvement were recruited, who received dexamethasone and colchicine for the first 2 weeks, then they were categorized into "sustained triple-therapy (ST)" (n = 231) and "colchicine to triple-therapy (CT)" (n = 124) groups respectively: for ST group, patients received colchicine, thalidomide plus TGP from Month (M)0.5 to M12; for CT group, patients received colchicine from M0.
[Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Zhong-shan People' s Hospital, Zhongshan 528403, Guangdong, China.
Systemic lupus erythematosus (SLE) is a diffuse, systemic autoimmune disorder that can impact multiple organs and systems, with patients exhibiting abnormal levels of various autoantibodies and immune markers in their serum. It is currently understood that dysregulation of B cells activation plays a pivotal role in the pathogenesis of SLE, as aberrantly activated B cells produce autoantibodies that inflict damage on multiple organs through complement activation and antibody-dependent cell-mediated cyto-toxicity. Traditional therapies for SLE may prove ineffective for certain patients or lead to adverse reactions.
View Article and Find Full Text PDFPersistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.
Eur J Neurol
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau; and Institut de Recerca Sant Pau, IR-SantPau, Barcelona, Spain.
Article Synopsis
- The study focuses on long-term outcomes and healthcare resource utilization in patients with generalized myasthenia gravis (gMG).
- About 220 patients were analyzed over eight years, showing significant improvement in daily living scores and a reduction in healthcare costs, although some patients continued to experience symptoms and drug-related adverse events.
- The findings suggest that while most patients experience positive outcomes, a minority still suffer from persistent symptoms and side effects, highlighting the ongoing burden of gMG on both patients and healthcare systems.
[Drug-drug interactions in critically ill patients].
Med Klin Intensivmed Notfmed
November 2024
Pharmakoepidemiologie, Institut für Pharmazeutische Wissenschaften, Eidgenössische Technische Hochschule (ETH) Zürich, Zürich, Schweiz.
Critically ill patients are at high risk of adverse drug-drug interactions. Pharmacodynamic drug-drug interaction may cause organ damage. Pharmacokinetic interactions are usually caused by inhibition or induction of enzymes of drug metabolism such as cytochrome P-450 isoenzymes or transporter proteins such as P‑glycoprotein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!